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Research on cancer and other conditions has shown flavonoids and sphingolipids to be food components capable of exerting chemoprotective action. Never-
theless, little is known about their effects on healthy individuals and their potential usefulness as therapeutic agents. The present study examined the possible
action of a dietary flavonoid, quercetin, and a sphingolipid, sphingomyelin, as functional foods in healthy animals. In particular, the effect on animal growth
of supplementing a conventional diet with one or other of these substances (0·5% quercetin and 0·05% sphingomyelin) was considered. Possible action
affecting intestinal physiology was also analysed by measuring the uptake of sugar and dipeptide, mediated by the Naþ-dependent sugar transporter
SGLT1 and the dipeptide Naþ/Hþ exchanger PEPT1 respectively, and the activity of related intestinal enzymes such as sucrase, maltase and aminopeptidase
N. Both substances seemed to modify small intestinal activity in healthy mice, altering intestinal enzymatic activity and nutrient uptake. These effects
observed in the small intestine did not impair normal development of the animals, as no differences in serum biochemical parameters or in organ and
body weights were found. The findings should help in elucidating the mechanisms of action of these food components with a view to their possible use
in the prevention of certain pathological conditions.
Quercetin: Sphingomyelin: SGLT1: PEPT1
As the relationship between health and diet becomes clearer and
our understanding of nutrition changes, we are becoming more
and more interested in knowing about what we are eating. In
recent years attention has focused increasingly on the roles of
functional foods in preventing various chronic conditions. Conse-
quently, flavonoids, sphingolipids, fibre and oligosaccharides,
food components derived from certain ingredients in fruits, veg-
etables and milk, have lately come to be widely studied; and
their roles in preventing and ameliorating various chronic diseases
(cardiovascular disease, allergies, cancer) have been described
(Liu, 2004; Halliwell et al. 2005), opening up a new research
field in nutrition.
Dietary flavonoids are known to help protect against several
pathological conditions, owing mainly to their antioxidant
activity, and their possible role as chemopreventive factors has
been described (Murota & Terao, 2003). Quercetin is the most
abundant flavonoid in the human diet (Boyer et al. 2004). It is
present as a glycoside in a variety of vegetables but reaches the
intestinal tract as an aglycone subsequent to the action of the
hydrolytic microflora (Gee et al. 2000; Nemeth et al. 2003).
Recent investigation has shown quercetin glycosides to exert an
influence on in vitro intestinal sugar absorption (Ader et al.
2001; Cermak et al. 2004).
Sphingolipids are structural and functional bioactive lipids
found in eggs, milk, meat, fish and soyabeans (Vesper et al.
1999) that regulate cell growth, differentiation and death, and
therefore have been looked upon as chemopreventive agents
(Lemonnier et al. 2003). Their activity as anticancer factors has
been described widely in the literature (Schmelz et al. 2000).
In the gastrointestinal tract sphingolipids are hydrolysed to cera-
mides and sphingoid bases that are absorbed rapidly by the intes-
tinal lining, where they can interact with several intracellular
signalling pathways (Schmelz et al. 2001; O’Prey et al. 2003;
Moskaug et al. 2004).
Little is known about the effects of these substances as food
supplements in the daily diets of healthy individuals. The mech-
anism of action and the bioavailability of each individual com-
pound must first be understood before there can be any
understanding of its bioavailability as a component in the com-
plex overall mixture of foodstuffs ingested. Accordingly, the
objective of the present study was to elucidate whether sup-
plementation of the conventional diet by either of these two bio-
active factors (the flavonoid quercetin and the sphingolipid
sphingomyelin) affects normal animal development and in par-
ticular activity by the intestinal tract (absorption and digestion).
The results of this research should contribute to our knowledge
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of these bioactive food components and our understanding of how
they act in the organism as a whole.
Materials and methods
Animals, diets and study design
Swiss mice, 28 d old and weighing about 20 g, were randomly
assigned to one of three dietary groups (twenty to thirty animals
per group). The mice were obtained from the colony of
Charles River Laboratory Animals in Barcelona, Spain. The mice
were housed in cages (five animals per cage) kept in a well-venti-
lated, thermostatically controlled room (22 ^ 28C) with a photo-
period of 12 h light and 12 h darkness. One group (group C) was
fed a control commercial diet that met all minimum requirements
for the proper development of growing animals (AIN-93), while
the other two groups were fed the same control diet supplemented
with either 0·5% quercetin (group Q) or 0·05% sphingomyelin
(group SM). Fresh diets were prepared weekly (according to
Table 1) with purified ingredients. All diets are isonitrogenous
and isoenergetic, and were kept refrigerated at 48C. Food and
water were available ad libitum to the mice. The body weight of
all animalswas recordedweekly.At the end of the 28 d experimental
period, the mice were anaesthetized and sacrificed by decapitation.
Trunk bloodwas collected for determinations of serum biochemical
parameters, and various organs were extracted and weighed. The
jejunum was carefully removed, flushed out with ice-cold saline,
frozen in liquid N2 and stored at 2808C until use in preparing the
brush-border-membrane vesicles (BBMV) for enzymatic assays
and measurement of the intestinal absorption of D-galactose and
glycylsarcosine. Before being frozen, a portion of the small intestine
and a portion of the colon (1 cm lengths)were taken for histological -
examination.
The Committee on Animal Care at the Public University
of Navarra reviewed and approved the animal care protocol
and the killing method to ensure compliance with the guidelines
of the Canadian Council on Animal Care (1993).
Histological analyses
Tissue samples collected for histological study were immediately
fixed in 4% formalin for 24 h. They were then dehydrated,
embedded in paraffin, sliced into 5mm sections and processed
by haematoxylin–eosin staining.
Preparation of mouse intestinal brush-border-membrane vesicles
Crude BBMV were obtained according to the method described by
Shirazi-Beechey et al. (1990). The BBMV were prepared from a
piece of small intestine taken from every animal in each diet
group. The mucosa was re-suspended in a buffer consisting of
100mM-mannitol and 2mM-HEPES adjusted to pH 7·1 with Tris.
The suspension was then homogenized using a Potter–Elvehjem
homogenizer (Braun, Melsungen, Germany) at 3000 rpm at 48C
for 1min. Next, MgCl2 was added to a final concentration of
10mM, and the mixture was incubated on ice with continuous ice-
cold shaking for 20min. The mixture was then centrifuged at
2000g for 15min, and the supernatantwas collected and centrifuged
at 27 000 g for 30min. Following centrifugation the supernatant was
discarded and the pellet re-suspended in a buffer consisting of
100mM-mannitol, 0·1mM-MgSO4 and 2mM-HEPES adjusted to
pH 7·4 with Tris. After a second precipitation with MgCl2, the mix-
ture was finally centrifuged at 27 000 g for 30min. The pellet was
then re-suspended in a buffer consisting of 300mM-mannitol,
0·1mM-MgSO4 and 10mM-HEPES adjusted to pH 7·4 with Tris.
The BBMV of ten mice were pooled, assayed for protein, diluted
to 10mg BBMV protein/ml, aliquoted and frozen in liquid N2.
The final BBMV preparation consisted of right-side microvilli
five-fold enriched for sucrase specific activity compared with the
initial homogenate.
Protein was assayed using the Bradford diagnostic kit (Bio-Rad
Laboratories, Barcelona, Spain) by complexing with Coomassie
Blue and reading the change in absorbance at 595 nm using
bovine albumin as standard.
Enzymatic activity
For each experimental diet group a number of BBMV aliquots
were thawed and pooled. Three replications of all enzymatic
assays were performed. Sucrase (E.C. 3·2·1·48) and maltase
(E.C. 3·2·1·20) activities were determined according to the
method described by Dahlqvist (1964) using sucrose and maltose
as substrates. After incubation in the presence of the appropriate
substrate for 30min, the glucose released was measured using Kit
A-510 from Sigma (St. Louis, MO, USA).
Alkaline phosphatase (E.C. 3·1·3·1) was assayed by measuring the
rate of hydrolysis of p-nitrophenyl phosphate to p-nitrophenol
(Uezato& Fujita, 1983), the results being expressed as U/mg protein.
The activity of a dipeptidase anchored on the brush-border mem-
brane of the enterocytes was also determined (Andria et al. 1980). In
the mouse and rat intestine, b-naphthylamides of L-amino acids are
hydrolysed more actively by particle-bound enzymes. Aminopepti-
dase N (E.C. 3·4·11·2) activity was measured spectrofluorometri-
cally using L-Gly-Pro-b-naphthylamide as substrate.
Sugar and dipeptide uptake by brush-border-membrane vesicles
Sugar and dipeptide uptake by the BBMV was measured using a
slightly modified version of the rapid filtration technique
Table 1. Composition of the three experimental diets
Diet
C Q SM
Ingredient (g/kg)
Sphingomyelin 0·0 0·0 0·5
Quercetin 0·0 5·0 0·0
Lactalbumin* 137·5 137·5 137·5
Sucrose 231·2 231·2 231·2
Corn starch 454·3 454·3 454·3
Olive oil 80·0 80·0 80·0
Mineral mix† 35·0 35·0 35·0
Vitamin mix† 10·0 10·0 10·0
Cellulose 50·0 50·0 50·0
Choline‡ 2·0 2·0 2·0
Calculated composition
Total protein (g/kg) 108·0 108·0 108·0
Crude energy (MJ/kg) 17·0 17·0 17·0
Metabolizable energy (MJ/kg) 16·0 16·0 16·0
C, control commercial diet; Q, control diet supplemented with quercetin; SM, control diet
supplemented with sphingomyelin.
* Lactalbumin: 80 % of pure protein, 4 % lactose (Sigma, St. Louis, MO, USA).
† AIN-93 (Dyets Inc., Bethlehem, PA, USA).
‡ 99 % in the bitartrate form (Sigma).
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developed by Hopfer et al. (1975). Three replications were per-
formed for each experimental diet group. D-Galactose uptake
was determined in the presence of an Naþ gradient at 378C.
The incubation medium had a pH of 7·4 and consisted of
0·1mM-D-galactose, 100mM-NaSCN, 100mM-mannitol, 0·1mM-
MgSO4, 10mM-HEPES and the radioactive substrate used as
tracer, D-[1-14C]galactose (0·037MBq/ml; Amersham Radio-
chemical Centre, UK). Glycylsarcosine uptake was measured at
278C in a pH 5·5 medium consisting of 1mM-glycylsarcosine,
280mM-mannitol, 0·1mM-MgSO4, 1mM-2-(N-morpholino)etha-
nesulfonic acid and the radioactive substrate used as tracer,
[1-3H]glycylsarcosine (0·370MBq/ml; Moravek Biochemicals,
Inc., Brea, CA, USA). At the times shown, incubation was
halted by adding ice-cold stop solution (150mM-KSCN,
0·25mM-phloridzin and 10mM-HEPES at pH 7·4 for the galactose
uptake determinations and 210mM-KCl and 2mM-HEPES at pH
7·5 for the dipeptide uptake determinations). The suspension
was poured immediately onto a cellulose nitrate filter (0·45mm,
25mm diameter; Sartorius, Edgewood, NY, USA) and the filter
was then washed twice in ice-cold stop solution and dissolved
in HiSafe 3 scintillation liquid for final measurement of radioac-
tivity using a b-counter.
Western blot analysis
Expression of transporters PEPT1 (Hþ/peptide cotransporter 1)
(Katsura & Inui, 2003) and SGLT1 (Naþ/glucose cotransporter 1)
in the BBMV from the different experimental diet groups was
detected using Western blotting. Samples were diluted in a buffer
consisting of 50mM-Tris–HCl, pH 6·8, 2% SDS, 10% glycerol,
5% 2-mercaptoethanol and 0·05 bromophenol blue, and boiled for
3min. The samples (50mg) were then loaded onto a 12% SDS/
PAGE mini-gel and separated in an electrophoresis unit for
60min. The separated proteins were transferred to a nitrocellulose
membrane (Hybond P; Amersham-Pharmacia Biotech, Barcelona,
Spain) at 250mA/100V and 48C for 2 h. The membranes were
blocked with Tris-buffered saline (100mM-Tris–HCl, pH 7·5,
0·9% NaCl) containing 0·1% Tween and 6% skimmed milk
powder at room temperature for 90min. PEPT1 and SCLT1 were
detected by incubating the membranes overnight with respectively
a specific affinity-purified rat PEPT1 antiserum kindly donated by
Dr Smith (University of Michigan, MI, USA) at a dilution of
1:500 and a rabbit SGLT1 polyclonal antibody (Chemicon Europe
Ltd, Hampshire, UK) at a dilution of 1:2500. After being washed
three times in Tris-buffered saline containing 0·1% Tween, the
membranes were incubated with the secondary antibody (E0466;
Dako Diagnostics, Barcelona, Spain) at a dilution of 1:2500 at
room temperature for 1 h. Finally, the immunoreactive proteins
were visualized by chemiluminiscence (Pierce Super Signal West
Dura; Pierce Biotechnology, Rockford, IL, USA). Bands were
quantified by densitometry using theQuantityOne program, version
4.5 (Bio-Rad Laboratories, Hertfordshire, UK), and values in the
presence of quercetin or sphingomyelin were normalized to those
for the control group.
Statistical analysis
Results given in the text and tables are expressed as means with
their standard errors. Statistical analysis of the data was per-
formed by a Kruskal–Wallis one-way ANOVA using SPSS ver-
sion 11.5 software (SPSS Inc., Chicago, IL, USA). Post hoc
comparisons were carried out by a least significant difference pro-
cedure. Differences among the groups were deemed statistically
significant when P,0·05.
Results
Animal growth
Including quercetin or sphingomyelin in the diet did not alter the
final body weight of the animals (Fig. 1), the weight gain (C: 0·43
(SE 0·03), Q: 0·38 (SE 0·02), SM: 0·36 (SE 0·01) g/d) or the body
growth index (C: 1·63 (SE 0·08), Q: 1·52 (SE 0·10), SM: 1·50
(SE 0·09)). These findings indicated that neither of the substances
tested affected the growth rate of the animals as compared with
the control group. Similarly, the serum biochemical parameters
measured did not exhibit any differences (Table 2) between the
various experimental diet groups other than certain hypoglycae-
mic and hypocholesterolaemic effects in group SM and a lower
triacylglycerol level in group Q.
The weights of the extracted organs (jejunum, pancreas, colon,
spleen, and liver) were likewise not altered by quercetin or sphin-
gomyelin intake (data not shown).
It therefore seems that adding these substances to animal diets
does not impair the animal’s normal growth rates or metabolic status.
Intestinal morphology
There were no differences in the morphology of the small intes-
tinal epithelium between the three experimental groups (data
not shown); hence intake of these food components at the
levels tested does not appear to be detrimental to normal develop-
ment of the small intestine.
Nutrient uptake and enzymatic activity in brush-border-membrane
vesicles
The effect of the supplemented diets on the intestinal physiology
of the growing mice was also determined. Fig. 2 shows that the
activity of the intestinal enzymes assayed was altered when quer-
cetin or sphingomyelin was added to the standard control diet.
Fig. 1. Body growth of animals fed the different experimental diets for 4
weeks: (V), control commercial diet; (B), control diet supplemented with
0·5 % quercetin; (O), control diet supplemented with 0·05 % sphingomyelin.
Values are means with their standard error shown by vertical bars
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In animals fed the diet supplemented with 0·5% quercetin,
there was a slight decrease in intestinal sucrase activity
(P¼0·078). Maltase activity was distinctly lower (P,0·001) in
both group Q and group SM. In contrast, aminopeptidase N
activity clearly increased (P,0·001) in the animals fed both the
experimentally supplemented diets, and alkaline phosphatase
activity also increased in group Q (P,0·001).
Similarly, the plots of the BBMV uptake assays demonstrated
that the presence of quercetin or sphingomyelin in the diet
inhibited D-galactose uptake while stimulating glycylsarcosine
uptake (Fig. 3). This effect was discernible only when nutrient
absorption was mediated by a transporter located in the brush-
border membrane (short assay times and an Naþ or Hþ gradient).
For longer incubation times (10min and 60min, respectively), the
sugar and the dipeptide tested entered the vesicles by a process of
diffusion that was not altered by the diet.
Looking at all these results together as a whole, it seems that
adding quercetin or sphingomyelin to the diet has a differing
effect on nutrient absorption and digestion, inhibiting the mechan-
isms involved in sugar absorption and digestion and enhancing
the mechanisms involved in peptide absorption and digestion.
Western blot analysis of SGLT1 and PEPT1 expression
To elucidate whether these effects on sugar and dipeptide uptake
are related to changes in the expression of the transporters
involved, the presence of the Naþ-dependent sugar transporter
SGLT1 and the dipeptide Naþ/Hþ exchanger PEPT1 on the
Fig. 2. Sucrase (a), maltase (b), alkaline phosphatase (c) and aminopeptidase N (d) enzymatic activity in intestinal brush-border-membrane vesicles obtained
from mice fed the different experimental diets (C, control commercial diet; Q, control diet supplemented with 0·5 % quercetin; SM, control diet supplemented with
0·05 % sphingomyelin) for 4 weeks. Values are means with their standard error shown by vertical bars for nine determinations from three different experiments.
Mean values were significantly different from those of the control group: †P¼0·078, ***P,0·001
Table 2. Serum biochemical parameters of the animals fed the different experimental diets for 4 weeks
(Mean values with their standard errors)
Diet
C Q SM
Parameter (n=20) Mean SE Mean SE Mean SE
Glucose (mg/dl) 158·72 6·83 163·31 9·96 146·29 9·85
Urea (mg/dl) 57·41 2·54 50·00 2·42 51·65 3·11
Protein (g/dl) 3·61 0·08 3·79 0·12 3·66 0·12
Albumin (g/dl) 2·81 0·05 2·79 0·057 2·67 0·12
Aspartate aminotransferase (U/l) 55·50 3·56 48·21 4·43 50·35 5·82
Alanine aminotransferase (U/l) 15·10 1·42 13·42 0·88 14·18 1·20
Lactate dehydrogenase (U/l) 438·34 36·62 411·42 31·32 384·23 38·26
a-Amylase (U/L) 7120·80 208·26 7614·21 300·0 6877·58 229·30
Cholesterol (mg/dl) 105·93 3·55 108·63 4·0 100·94 4·86
Triacylglycerols (mg/dl) 71·65 5·06 64·89 3·57 73·88 5·08
HDL-cholesterol (mg/dl) 92·27 2·96 93·47 3·24 89·94 3·91
Cholesterol:HDL-cholesterol 1·14 0·01 1·16 0·01 1·12 0·01
C, control commercial diet; Q, control diet supplemented with 0·5 % quercetin; SM, control diet supplemented with 0·05 % sphingo-
myelin.
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apical membrane of the enterocytes was analysed by Western
blotting.
Fig. 4 depicts a clear increase in expression of the PEPT1 trans-
porter in the BBMV solutions obtained from the animals in group
SM and a slight decrease in those from group Q, compared with
group C. It thus seems that the effect of higher dipeptide uptake in
the two supplemented groups was due to different mechanisms for
quercetin and for sphingomyelin.
Expression of SGLT1 in the two supplemented diet groups
increased compared with the control group and was highest for
group Q. These results suggest that the lower galactose absorption
observed in the uptake assays described above could be brought
about by a loss of transporter affinity for its substrate.
Discussion
The roles of quercetin and sphingomyelin in the development
of several chronic diseases have been discussed widely in the
literature, and it has been suggested that they may possibly act
as bioactive factors. However, little is known about the effects
of these substances on healthy individuals and their potential
for use as preventive or therapeutic agents. This makes it necess-
ary to analyse their effects on healthy organisms in order to be
able to formulate reliable recommendations concerning their
possible use in preventive therapies and establish a scientifically
sound basis for determining their effective doses, possible side-
effects, etc.
The present study analysed the effects of quercetin and sphin-
gomyelin on the growth, development and intestinal physiology
of healthy mice, since the intestinal barrier regulates the entry
of nutrients and other substances that affect the individual’s nutri-
tional status. Maintaining the proper nutritional status is of great
importance in the prevention and development of illness.
The doses of quercetin and sphingomyelin tested were selected
based on other reports (Lemonnier et al. 2003) and data that have
estimated levels of daily intake in man as ranging between 10 and
20mg for quercetin (De Vries et al. 1997) and 0·3 and 0·5 g
(0·01–0·02% of the diet by weight) for sphingolipids (Vesper
et al. 1999; Merrill et al. 1997) in the populations of Western
societies. Accordingly, since the mice had a total food intake of
approximately 5 g/d, supplementation of 0·5% quercetin in the
experimental diet represented a daily intake of 25mg quercetin,
which is in the range of values reported for intake by human sub-
jects. Supplementation of 0·05% sphingomyelin was likewise
equivalent to amounts that have been observed to exert detectable
effects in different studies performed on mice (Schmelz et al.
1996) and was close to the estimated intake levels for man men-
tioned above.
The normal growth rate and metabolic status of the animals
were not affected by inclusion of either substance in the diets,
suggesting that at the doses tested they could be added as dietary
supplements without detrimental effect. This finding is in agree-
ment with other studies on mice performed by other workers,
which have shown that administering sphingomyelin in the diet
did not alter weight gain by animals (Dillehay et al. 1994; Sang
& Sung, 2003).
In contrast, the determinations of activity by the small intestine
revealed that ingesting quercetin or sphingomyelin did affect
intestinal enzymatic activity and nutrient absorption, although
the morphology of the jejunum was not altered. Unexpectedly,
while the activity of enzymes involved in glucose absorption
(sucrase and maltase) decreased, the activity of enzymes involved
in dipeptide absorption (aminopeptidase N) increased. This was
consistent with the results of the assays of galactose and glycyl-
sarcosine uptake by the BBMV. The presence of quercetin or
sphingomyelin in the diet inhibited D-galactose uptake and stimu-
lated glycylsarcosine uptake. Recently, other researchers observed
quercetin to have a similar effect in glucose uptake studies per-
formed using porcine intestinal BBMV (Cermak et al. 2004)
and isolated rat adipocytes (Strobel et al. 2005). In addition, regu-
lation by quercetin of intestinal disaccharidases in diabetic rats
has also been described (Ramachandra et al. 2005).
These findings could be explained by an action of quercetin or
sphingomyelin on transporter expression levels, altering transpor-
ter availability on the apical membrane of the enterocytes. To
confirm this hypothesis, expression of the Naþ-dependent sugar
transporter SGLT1 and the dipeptide Naþ/Hþ exchanger PEPT1
was measured by the Western blot method. These analyses
revealed changes in the expression of both PEPT1 and SGLT1
in mice fed the experimental diets supplemented with quercetin
Fig. 3. Uptake of (a) 1 mM-D-galactose (in the presence of an Naþ gradient
at 378C and pH 7·4) and (b) 0·1 mM-glycylsarcosine (in the presence of an
Hþ gradient at 278C and pH 5·5) by intestinal brush-border-membrane ves-
icles obtained from mice fed the different experimental diets (V, control com-
mercial diet; B, control diet supplemented with 0·5 % quercetin; O, control
diet supplemented with 0·05 % sphingomyelin) for 4 weeks. Values are
means with their standard error shown by vertical bars for one representative
experiment of three different determinations. Mean values were significantly
different from those of the control group: *P,0·05, **P,0·01
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and sphingomyelin, expression of SGLT1 being increased and
expression of PEPT1 being decreased, although the latter only
in the presence of supplementation with quercetin.
It therefore seems that even though similar effects were
observed in the BBMV uptake assays, regulation of the dipeptide
transporter by these two substances differs. The PEPT1 transpor-
ter is known to be regulated by diet (Shiraga et al. 1999; Adibi,
2003), and the higher expression of this transporter in the sphin-
gomyelin-supplemented diet could be due in part to lower levels
of di- or tripeptides in the intestinal lumen brought about by the
increased aminopeptidase N activity recorded. It has also been
suggested that quercetin and sphingomyelin or their metabolic
derivatives enter the enterocytes and might interact with various
intracellular signalling pathways (O’Prey et al. 2003), which
in turn affects regulation of transporter turnover processes.
Stimulation of PEPT1 activity by quercetin by increasing the
maximal rate of uptake has already been demonstrated in other
studies (Wenzel et al. 2001).
Surprisingly, however, the lower galactose uptake in the
BBMV was consistent with higher expression of the SGLT1
transporter, suggesting that quercetin and sphingomyelin might
affect membrane insertion of the protein, thereby altering its
affinity for its substrate and decreasing its transport activity.
In addition, lower sugar levels in the intestinal lumen due to
the decreased activity of maltase and sucrase referred to
above could also contribute to this effect on galactose
absorption.
The regulation of nutrient uptake observed in the small intes-
tine did not impair normal development of the animals, as no
differences in serum biochemical parameters or in organ and
body weights were found. This fact could be interesting in malnu-
trition situations established as a result of some pathological dis-
eases such as cancer, cirrhosis and inflammatory bowel disease.
In conclusion, both these bioactive substances seem clearly to
modify small intestine activity in healthy mice, altering intestinal
enzymatic activity and nutrient uptake. It is therefore of great
interest to elucidate all possible beneficial and/or detrimental
action that these compounds might have on the organism as a
whole before recommending them for use in the therapeutic
treatment of different pathological conditions. Further study is
needed to identify the mechanisms of action by quercetin
and sphingomyelin on intestinal physiology in order to lay out
the scientific basis for their use in the prevention of chronic
diseases.
Acknowledgements
We thank Dr Smith from the University of Michigan who kindly
donated the PEPT1 antibody used in the present study. This work
was supported by a grant from the Health Department of the
Navarra Government.
References
Ader P, Blo¨ck M, Pietzsch S & Wolffram S (2001) Interaction of querce-
tin glucosides with the sodium/glucose cotransporter (SGLT1). Cancer
Lett 162, 175–180.
Adibi SA (2003) Regulation of the intestinal oligopeptide transporter
(Pept-1) in health and disease. Am J Physiol Gastrointest Liver Physiol
285, G779–G788.
Andria G, Cucchiara S, De Vizia B, De Ritis G, Masaka G & Aurichio S
(1980) Brush border and cytosol peptidase activities of human small
intestine in normal subjects and celiac patients. Pediatr Res 14,
812–818i.
Boyer J, Brown D & Liu RH (2004) Uptake of quercetin and quercetin
3-glucoside from whole onion and apple peel extracts by Caco-2 cell
monolayers. J Agric Food Chem 52, 7172–7179.
Cermak R, Landgraf S & Wolffram S (2004) Quercetin glucosides inhibit
glucose uptake into brush-border-membrane vesicles of porcine jeju-
num. Br J Nutr 91, 849–855.
Dahlqvist A (1964) Method for assay of intestinal disaccharidases. Anal
Biochem 7, 18–25.
Fig. 4. Representative Western blot (left) and corresponding densitometric analysis (right) showing regulation of (a) the dipeptide Naþ/Hþ exchanger PEPT1 and
(b) the Naþ-dependent sugar transporter SGLT1 in intestinal brush-border-membrane vesicles obtained from mice fed the different experimental diets (C, control
commercial diet; Q, control diet supplemented with 0·5 % quercetin; SM, control diet supplemented with 0·05 % sphingomyelin) for 4 weeks. As expected, in both
cases a band of approximately 75–80 kDa corresponding to the protein under study was observed. In the densitometric analysis, values are means with their stan-
dard error shown by vertical bars for three different blots
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